About-cancer/treatment/clinical-trials/disease/melanoma/treatment

Kuvura Ibizamini bya Clinical kuri Melanoma

Igeragezwa rya Clinical ni ubushakashatsi bwubushakashatsi burimo abantu. Ibizamini byamavuriro kururu rutonde ni ibya melanoma. Ibigeragezo byose kurutonde bishyigikiwe na NCI.

Amakuru yibanze ya NCI kubyerekeye ibizamini byamavuriro asobanura ubwoko nicyiciro cyibigeragezo nuburyo bikorwa. Igeragezwa rya Clinical rireba uburyo bushya bwo kwirinda, gutahura, cyangwa kuvura indwara. Urashobora gushaka gutekereza kubijyanye no kwitabira ikizamini cyamavuriro. Vugana na muganga wawe kugirango agufashe guhitamo niba umwe akubereye.

Ikigeragezo 1-25 cya 260 1 2 3 ... 11 Ibikurikira>

Ubuvuzi bugamije kuyobora buyobowe na testi ya genetike mukuvura abarwayi bafite ibibyimba bigezweho bya Lymphoma, Lymphoma, cyangwa Myeloma myinshi (Ikigeragezo CY'IMIKINO)

Iki cyiciro cya II CY'IMIKORESHEREZE yiga uburyo ubuvuzi buyobowe nogupima geneti bukora kubarwayi bafite ibibyimba bikomeye cyangwa lymphoma byateye imbere nyuma yumurongo umwe wubuvuzi busanzwe cyangwa bidafite uburyo bwo kuvura buhari. Ibizamini bya genetike bireba ibintu byihariye (genes) byingirangingo yibibyimba byabarwayi. Abarwayi bafite imiterere idasanzwe (nka mutation, amplification, cyangwa translocations) barashobora kungukirwa cyane nubuvuzi bwibasira ibibyimba byabo bidasanzwe. Kumenya ubwo buryo budasanzwe bwambere bishobora gufasha abaganga gutegura uburyo bwiza bwo kuvura abarwayi bafite ibibyimba bikomeye, lymphoma, cyangwa myeloma myinshi.

Aho uherereye: 1189

Pembrolizumab mu kuvura abarwayi bafite icyiciro cya III-IV Ibyago byinshi Melanoma mbere na nyuma yo kubagwa

Iki cyiciro cya II ikigeragezo cyiga uburyo pembrolizumab ikora mbere na nyuma yo kubagwa mu kuvura abarwayi bafite icyiciro cya III-IV cya melanoma ifite ibyago byinshi. Immunotherapy hamwe na antibodiyite za monoclonal, nka pembrolizumab, irashobora gufasha umubiri wumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo zikura no gukwirakwira. Gutanga pembrolizumab mbere na nyuma yo kubagwa birashobora gukora neza mukuvura melanoma.

Aho uherereye: 709

Dabrafenib na Trametinib Bikurikirwa na Ipilimumab na Nivolumab cyangwa Ipilimumab na Nivolumab Bikurikirwa na Dabrafenib na Trametinib mu kuvura abarwayi bafite icyiciro cya III-IV BRAFV600 Melanoma

Igeragezwa ryicyiciro cya III ryiga uburyo bwo kuvura neza hamwe na ipilimumab na nivolumab bikurikirwa na dabrafenib na trametinib bikora bikabigereranya nubuvuzi bwambere hamwe na dabrafenib na trametinib bikurikirwa na ipilimumab na nivolumab mukuvura abarwayi bafite icyiciro cya III-IV melanoma irimo mutation izwi nka. BRAFV600 kandi ntishobora gukurwaho no kubagwa (bidashoboka). Immunotherapy hamwe na antibodiyite za monoclonal, nka ipilimumab na nivolumab, birashobora gufasha umubiri wumubiri kwibasira kanseri, kandi bishobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira. Dabrafenib na trametinib birashobora guhagarika ikibyimba kibasira gene BRAFV600.

Aho uherereye: 712

Ipilimumab hamwe na Nivolumab cyangwa idafite mu kuvura abarwayi bafite Melanoma Ari Icyiciro cya IV cyangwa Icyiciro cya III kandi ntishobora gukurwaho no kubagwa

Iki cyiciro cya II ikigeragezo cyiga uburyo ipilimumab ifite cyangwa idafite nivolumab ikora mukuvura abarwayi bafite melanoma iri murwego rwa IV cyangwa icyiciro cya III kandi ntishobora gukurwaho no kubagwa. Immunotherapy hamwe na antibodiyite za monoclonal, nka ipilimumab na nivolumab, birashobora gufasha umubiri wumubiri kwibasira kanseri, kandi bishobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira.

Aho uherereye: ahantu 600

Pembrolizumab mu kuvura abarwayi hamwe na Desmoplastique Melanoma ishobora cyangwa idashobora gukurwaho no kubagwa

Iki cyiciro cya kabiri cyikigereranyo cyiga uburyo pembrolizumab ikora neza mukuvura abarwayi bafite desmoplastique melanoma (DM) ishobora cyangwa idashobora gukurwaho no kubagwa (bidashoboka). Antibodiyite za Monoclonal, nka pembrolizumab, zirashobora guhagarika poroteyine zihariye zishobora gushimangira ubudahangarwa bw'umubiri no kugenzura imikurire y'ibibyimba.

Aho uherereye: 202

Kwiga Igitebo cya Entrectinib (RXDX-101) yo kuvura abarwayi bafite ibibyimba bikomeye bibika NTRK 1/2/3 (Trk A / B / C), ROS1, cyangwa ALK Gene Rearrangements (Fusions)

Ubu ni label ifunguye, igizwe na multicenter, icyiciro cya 2 cyicyiciro cya 2 cyiga kuri entrectinib (RXDX-101) kugirango bavure abarwayi bafite ibibyimba bikomeye bibika NTRK1 / 2/3, ROS1, cyangwa ALK ya gene ya ALK. Abarwayi bazahabwa ibiseke bitandukanye ukurikije ubwoko bwibibyimba hamwe na gene fusion.

Aho uherereye: ahantu 26

Umutekano ningirakamaro bya Pembrolizumab Ugereranije na Placebo muri Resected ibyago byinshi Icyiciro cya kabiri Melanoma (MK-3475-716 / KEYNOTE-716)

Ubu bushakashatsi bugizwe nibice 2 buzasuzuma umutekano ningirakamaro bya pembrolizumab (MK-3475) ugereranije na placebo mubitabiriye hamwe no kubagwa bafite ibyago byinshi byo mu cyiciro cya kabiri melanoma. Abazitabira Igice cya 1 bazahabwa pembrolizumab cyangwa placebo muburyo bubiri-buhumyi bugera kuri 17. Abitabiriye amahugurwa bahabwa umwanya wa bo cyangwa bahagaritse kwivuza nyuma yo guhabwa inzinguzingo 17 za pembrolizumab mu gice cya 1, ntibahura n’indwara mu gihe cy’amezi 6 nyuma yo kurangiza pembrolizumab mu gice cya 1, kandi ntibahagarike kwivuza na pembrolizumab kugira ngo indwara yongere kubaho cyangwa kutihanganirwa, barashobora kwemererwa yakira inzinguzingo zigera kuri 35 za pembrolizumab mugice cya 2 mugushushanya-label. Igitekerezo cyibanze cyubu bushakashatsi nuko pembrolizumab yongerera ubuzima kubaho (RFS) ugereranije na placebo.

Aho uherereye: ahantu 25

Nivolumab hamwe na Ipilimumab cyangwa idafite mu kuvura abarwayi bato bafite ibibyimba bisubirwamo cyangwa bikabije cyangwa Sarcomas

Iki cyiciro cya I / II cyiga ingaruka mbi nigipimo cyiza cya nivolumab mugihe gitanzwe hamwe na ipilimumab cyangwa kitarimo kugira ngo barebe uburyo bakora neza mukuvura abarwayi bato bafite ibibyimba bikomeye cyangwa sarcomasi byagarutse (byongeye) cyangwa ntibitabira kwivuza (byongeye) kwanga). Immunotherapy hamwe na antibodiyite za monoclonal, nka nivolumab na ipilimumab, irashobora gufasha sisitemu yumubiri yumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira. Kugeza ubu ntiharamenyekana niba nivolumab ikora neza wenyine cyangwa hamwe na ipilimumab mu kuvura abarwayi bafite ibibyimba bikomeye cyangwa byanga bikunze cyangwa sarcomas.

Aho uherereye: ahantu 24

Kwiyongera kwa Dose Kwiyongera no Kwagura Cohort Kwiga NKTR-214 ifatanije na Nivolumab hamwe nubundi buvuzi bwo kurwanya kanseri ku barwayi bafite ibibyimba bikomeye bikabije (PIVOT-02)

Muri ubu bushakashatsi bugizwe n'ibice bine, NKTR-214 izatangwa ifatanije na nivolumab mu gice cya 1, ifatanije na nivolumab hamwe na chimiotherapie zitandukanye cyangwa idafite igice cya 2, hamwe na nivolumab na ipilimumab mu gice cya 3 & 4. Mu gice cya 1, the Basabwe Icyiciro cya 2 Dose (RP2D) ya NKTR-214 ifatanije na nivolumab bizamenyekana. Mu gice cya 2, NKTR-214 hamwe na nivolumab kuri RP2D bizasuzumwa nk'ubuvuzi bwo ku murongo wa mbere na / cyangwa nk'ubuvuzi bwa kabiri cyangwa ubwa gatatu mu barwayi batoranijwe barwaye Melanoma, Carcinoma y'impyiko (RCC), Kanseri y'ibihaha itari mito mito (NSCLC) ), Urceliyale Carcinoma (UC), Kanseri y'ibere metastatike (mBC) na Kanseri yibara (CRC). Byongeye kandi, mu gice cya 2, hazamenyekana RP2D ya NKTR-214 hamwe na nivolumab hamwe na chimiotherapie zitandukanye hamwe na rejime mubice bitandukanye by’abarwayi ba NSCLC. Mu gice cya 3, uburyo butandukanye bwo guhuza ibice bitatu bya NKTR-214 hiyongereyeho nivolumab na ipilimumab bizasuzumwa mubarwayi batoranijwe bafite RCC, NSCLC, Melanoma, na UC. Mu gice cya 4, umutekano n’ingirakamaro byo guhuza inyabutatu bizasuzumwa kurushaho mu barwayi batoranijwe bafite RCC, NSCLC, Melanoma na UC.

Aho uherereye: ahantu 22

Icyiciro 1 / 1b Kwiga Gusuzuma Umutekano no Kwihanganirana bya CPI-444 Wenyine no Guhuza na Atezolizumab muri Kanseri Yateye imbere

Nicyiciro cya 1 / 1b gifungura-label, multicenter, ubushakashatsi-bwo guhitamo dose ya CPI-444, molekile ntoya yo mu kanwa yibasira reseptor ya adenosine-A2A kuri T-lymphocytes nizindi selile za sisitemu yumubiri. Iki kigeragezo kiziga ku mutekano, kwihanganira, no kurwanya ibibyimba bya CPI-444 nkumukozi umwe kandi bifatanije na atezolizumab, inzitizi ya PD-L1 irwanya ibibyimba bitandukanye. CPI-444 ibuza adenosine guhuza na reseptor ya A2A. Adenosine ihagarika ibikorwa byo kurwanya ibibyimba bya selile T nizindi selile.

Aho uherereye: ahantu 22

Ubushakashatsi bwa Pembrolizumab (MK-3475) mubitabiriye abana hamwe na Tumor Advanced Solid Tumor cyangwa Lymphoma (MK-3475-051 / KEYNOTE-051)

Ubu ni ubushakashatsi bwibice bibiri byerekeranye na pembrolizumab (MK-3475) mubitabiriye abana bafite ubwoko bumwe na bumwe bwa kanseri ikurikira: - melanoma yateye imbere (amezi 6 kugeza <18 ans), - yateye imbere, yisubiraho cyangwa yanga gahunda yurupfu- ligand 1 (PD-L1) -positif malignant ikibyimba gikomeye cyangwa izindi lymphoma (amezi 6 kugeza <18 ans), - yisubiramo cyangwa yananijwe na lymphoma ya Hodgkin (rrcHL) (imyaka 3 kugeza <18 ans), cyangwa - yateye imbere gusubiramo cyangwa kwanga microsatellite-ihungabana-hejuru (MSI-H) ibibyimba bikomeye (amezi 6 kugeza <18 ans). Igice cya 1 kizasanga urugero rwinshi rwihanganirwa (MTD) / ikinini ntarengwa cyatanzwe (MAD), kwemeza igipimo, hanyuma ushakishe icyiciro cya 2 cyateganijwe (RP2D) cyo kuvura pembrolizumab. Igice cya 2 kizakomeza gusuzuma umutekano ningirakamaro kuri RP2D y'abana. Igitekerezo cyibanze cyubu bushakashatsi nuko imiyoborere yimitsi (IV) ya pembrolizumab kubana bafite melanoma yateye imbere; PD-L1 nziza yateye imbere, isubirwamo cyangwa yangiritse ikibyimba gikomeye cyangwa izindi lymphoma; ikibyimba cyateye imbere, gisubiramo cyangwa cyananiranye MSI-H ikibyimba gikomeye; cyangwa rrcHL, bizavamo Igipimo cyo Gusubiza (ORR) kirenze 10% byibuze bumwe murubwo bwoko bwa kanseri. Hamwe n'ivugururwa rya 8, kwiyandikisha kw'abitabiriye bafite ibibyimba bikomeye ndetse n'abitabiriye kuva ku mezi 6 kugeza ku myaka 12 hamwe na melanoma. Kwiyandikisha kwabitabiriye bafite imyaka 12 kugeza kumyaka 18 hamwe na melanoma birakomeje. Kwiyandikisha kubitabiriye hamwe na MSI-H ibibyimba bikomeye nabyo birakomeza. gusubiramo cyangwa kuvunika MSI-H ikibyimba gikomeye; cyangwa rrcHL, bizavamo Igipimo cyo Gusubiza (ORR) kirenze 10% byibuze bumwe murubwo bwoko bwa kanseri. Hamwe n'ivugururwa rya 8, kwiyandikisha kw'abitabiriye bafite ibibyimba bikomeye ndetse n'abitabiriye kuva ku mezi 6 kugeza ku myaka 12 hamwe na melanoma. Kwiyandikisha kwabitabiriye bafite imyaka 12 kugeza kumyaka 18 hamwe na melanoma birakomeje. Kwiyandikisha kubitabiriye hamwe na MSI-H ibibyimba bikomeye nabyo birakomeza. gusubiramo cyangwa kuvunika MSI-H ikibyimba gikomeye; cyangwa rrcHL, bizavamo Igipimo cyo Gusubiza (ORR) kirenze 10% byibuze bumwe murubwo bwoko bwa kanseri. Hamwe n'ivugururwa rya 8, kwiyandikisha kw'abitabiriye bafite ibibyimba bikomeye ndetse n'abitabiriye kuva ku mezi 6 kugeza ku myaka 12 hamwe na melanoma. Kwiyandikisha kwabitabiriye bafite imyaka 12 kugeza kumyaka 18 hamwe na melanoma birakomeje. Kwiyandikisha kubitabiriye hamwe na MSI-H ibibyimba bikomeye nabyo birakomeza.

Aho uherereye: ahantu 19

Umutekano ningirakamaro bya IMCgp100 Guhitamo Guhitamo Iperereza muri Advanced Uveal Melanoma

Kugirango dusuzume ubuzima rusange bwa HLA-A * 0201 abarwayi bakuze bafite abarwayi ba mbere batavuwe bakira IMCgp100 ugereranije nuhitamo Iperereza rya dacarbazine, ipilimumab, cyangwa pembrolizumab.

Aho uherereye: ahantu 18

Enapotamab Vedotin (HuMax-AXL-ADC) Inyigisho yumutekano kubarwayi bafite ibibyimba bikomeye

Ikigamijwe mu igeragezwa ni ukumenya igipimo ntarengwa cyihanganirwa no gushyiraho umwirondoro w’umutekano wa HuMax-AXL-ADC mu baturage bavanze n’abarwayi bafite ibibyimba bikomeye;

Aho uherereye: ahantu 18

Inyigo ya XmAb®20717 mubintu hamwe na Byatoranijwe Bikomeye Byibibyimba

Iki nicyiciro cya 1, igipimo cyinshi, ubushakashatsi bwiyongera bwa dose escalation kugirango busobanure MTD / RD nuburyo bwa XmAb20717, gusobanura umutekano no kwihanganirana, gusuzuma PK na immunogenicite, no gusuzuma mbere na mbere ibikorwa byo kurwanya ibibyimba bya XmAb20717 mubisomo byatoranijwe ibibyimba bikomeye.

Aho uherereye: ahantu 15

Talimogene Laherparepvec na Pembrolizumab mu kuvura abarwayi bafite icyiciro cya III-IV Melanoma

Iki cyiciro cya II cyikigereranyo cyiga uburyo talimogene laherparepvec na pembrolizumab bikora neza mukuvura abarwayi bafite icyiciro cya III-IV melanoma. Ubuvuzi bwibinyabuzima, nka talimogene laherparepvec, bukoresha ibintu bikozwe mu binyabuzima bizima bishobora gukangura cyangwa guhagarika ubudahangarwa bw'umubiri mu buryo butandukanye kandi bikabuza ingirabuzimafatizo zikura. Immunotherapy hamwe na antibodiyite za monoclonal, nka pembrolizumab, irashobora gufasha umubiri wumubiri gutera kanseri, kandi irashobora kubangamira ubushobozi bwingirabuzimafatizo zikura no gukwirakwira. Gutanga talimogene laherparepvec na pembrolizumab birashobora gukora neza mukuvura abarwayi barwaye melanoma mugabanya ikibyimba.

Aho uherereye: ahantu 16

Dabrafenib, Trametinib, na Navitoclax mukuvura abarwayi hamwe na BRAF Mutant Melanoma cyangwa Ibibyimba bikomeye Bipima cyangwa bidashobora gukurwaho no kubagwa

Iki cyiciro cya I / II cyiga ingaruka mbi nigipimo cyiza cya dabrafenib, trametinib, na navitoclax no kureba uburyo bakora neza mukuvura abarwayi bafite BRAF mutant melanoma cyangwa ibibyimba bikomeye byakwirakwiriye mubindi bice byumubiri cyangwa bidashobora gukurwaho kubagwa. Dabrafenib, trametinib, na navitoclax irashobora guhagarika imikurire ya selile yibibyimba ihagarika imisemburo ikenewe kugirango imikurire ikure.

Aho uherereye: ahantu 24

Ubushakashatsi bwa Avelumab Mufatanije nizindi Immunotherapie Kanseri Yindwara Yambere (JAVELIN Medley)

Ubu ni icyiciro cya 1b / 2 dose-optimizasiyo yo gusuzuma umutekano, pharmacokinetics, pharmacodynamics, nibikorwa bya antitumor primaire ya avelumab (MSB0010718C) ifatanije nubundi buryo bwo gukingira kanseri kubarwayi bafite ibibyimba bikomeye byateye imbere cyangwa metastatike. Intego yibanze nugusuzuma umutekano nibimenyetso byambere byerekana imikorere ya avelumab itandukanye hamwe nizindi miti ikingira kanseri, guhitamo uburyo bwo gufata imiti nkuko bikwiye, murukurikirane rwibimenyetso.

Aho uherereye: ahantu 12

Iperereza ryakozwe na Immuno-therapy Kwiga gusuzuma Umutekano, Ubworoherane ningaruka za Anti-LAG-3 Hamwe na Anti-PD-1 mu kuvura ibibyimba bikomeye.

Intego yubu bushakashatsi ni ugusuzuma umutekano, kwihanganira no gukora neza imiti igerageza BMS-986016 yatanzwe wenyine kandi ifatanije na nivolumab ku barwayi bafite ibibyimba bikomeye byakwirakwiriye kandi / cyangwa bidashobora gukurwaho no kubagwa. Ubwoko bwibibyimba bikurikira bikubiye muri ubu bushakashatsi: Kanseri y'ibihaha itari ntoya (NSCLC), kanseri yo mu gifu, kanseri y'umwijima, kanseri y'impyiko, kanseri y'uruhago, kanseri y'udukoko two mu mutwe no mu ijosi, na melanoma, bitigeze bibaho mbere. bivurwa hakoreshejwe ubudahangarwa. NSCLC na melanoma Bigeze kuvurwa hakoreshejwe immunotherapy.

Aho uherereye: ahantu 12

Umutekano, Ubworoherane na PK Kwiga DCC-2618 mubarwayi bafite Indwara mbi

Iki nicyiciro cya 1, fungura-label, ubushakashatsi bwambere-bwabantu (FIH) dose-escalation igamije gusuzuma umutekano, kwihanganira, pharmacokinetics (PK), pharmacodynamics (PD) nibikorwa byabanjirije antitumor ya DCC-2618, byatanzwe kumanwa. (PO), mu barwayi bakuze bafite indwara mbi. Ubushakashatsi bugizwe n'ibice 2, icyiciro cya dose-escalation nicyiciro cyo kwaguka.

Aho uherereye: ahantu 12

Ubushakashatsi bwa NKTR-214 Yahujwe na Nivolumab vs Nivolumab Wenyine mubitabiriye hamwe na Melanoma ya mbere itavuwe neza cyangwa idakoreshwa.

Intego yubu bushakashatsi ni ukugerageza gukora neza (uko ibiyobyabwenge bikora neza), umutekano, no kwihanganira imiti yiperereza yitwa NKTR-214, iyo ihujwe na nivolumab na nivolumab yatanzwe wenyine mubitabiriye hamwe na kanseri y'uruhu ya melanoma itavuwe neza yaba ari idashobora gukurwaho kubagwa cyangwa gukwirakwira

Aho uherereye: ahantu 10

Inyigo ya Relatlimab Yongeyeho Nivolumab na Nivolumab Wenyine mubitabiriye hamwe na Melanoma Yambere

Intego yubu bushakashatsi ni ukumenya niba nivolumab ifatanije na relatlimab ikora neza kuruta nivolumab yonyine mu kuvura melanoma cyangwa melanoma idashobora gukwirakwira.

Aho uherereye: ahantu 13

Pembrolizumab na Ipilimumab mu kuvura abarwayi hamwe na Melanoma Yambere Yavuwe

Iki cyiciro cya II cyikigereranyo cyiga uburyo pembrolizumab na ipilimumab bikora neza mukuvura abarwayi bafite melanoma yavuwe mbere yakwirakwiriye mubindi bice byumubiri. Immunotherapy hamwe na antibodiyite za monoclonal, nka pembrolizumab na ipilimumab, birashobora gufasha umubiri wumubiri kwibasira kanseri, kandi bishobora kubangamira ubushobozi bwingirabuzimafatizo yibibyimba gukura no gukwirakwira.

Aho uherereye: ahantu 10

Kwiga Clinical ya CMP-001 muguhuza na Pembrolizumab cyangwa nka Monotherapy

Ubu bushakashatsi buzakorwa mu bice bibiri: Igice cya 1 kizakorwa hifashishijwe igishushanyo cya Dose Escalation no Kwagura. Igice cya 1 Dose Escalation Icyiciro cyubu bushakashatsi kizagaragaza igipimo cyizewe kandi cyihanganirwa kugirango gisuzumwe neza mugice cya 1 Icyiciro cyo Kwagura. Igice cya 2 cyubushakashatsi kizakorwa kibangikanye nicyiciro cya 1 cyo kwagura icyiciro kandi kizasuzuma umutekano ningirakamaro bya CMP-001 mugihe bizakorwa nka mitiweli.

Aho uherereye: ahantu 12

Icyiciro 1b / 2 Ikigeragezo cya Lenvatinib (E7080) Wongeyeho Pembrolizumab mubintu bifite ibibyimba byatoranijwe byatoranijwe

Nibimenyetso bifunguye Icyiciro 1b / 2 cya lenvatinib (E7080) wongeyeho pembrolizumab mubitabiriye bafite ibibyimba byatoranijwe. Icyiciro cya 1b kizagena kandi cyemeze igipimo ntarengwa cyihanganirwa (MTD) kuri lenvatinib ifatanije na miligarama 200 (mg) (imitsi itwara imitsi [IV], buri byumweru 3 [Q3W]) pembrolizumab mubitabiriye bafite ibibyimba bikomeye byatoranijwe (ni ukuvuga ibihaha bitari bito bito) kanseri, kanseri y'impyiko, kanseri ya endometrale, kanseri ya urothelia, kanseri y'udukoko twa kanseri yo mu mutwe no mu ijosi, cyangwa melanoma). Icyiciro cya 2 (Kwaguka) kizasuzuma umutekano ningirakamaro byoguhuza muri cohort 6 kuri MTD kuva Phase 1b (lenvatinib 20 mg / kumunsi kumunwa + pembrolizumab 200 mg Q3W, IV).

Aho uherereye: ahantu 10

Kwiga Lifileucel (LN-144), Autologous Tumor Yinjira muri Lymphocytes, mukuvura abarwayi hamwe na Melanoma Metastatike

Ubushakashatsi buteganijwe, intera interineti isuzuma uburyo bwo kuvura ingirabuzimafatizo (ACT) hifashishijwe LN-144 (autologique TIL) ikurikirwa na interleukin 2 (IL-2) nyuma ya lymphodepletion idasanzwe (NMA LD) ibanziriza gahunda.

Aho uherereye: ahantu 13

1 2 3 ... 11 Ibikurikira>